- Home
- CELC vs DCGO Comparison
CELC vs DCGO Comparison
Compare CELC & DCGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- DCGO
- Stock Information
- Founded
- CELC 2011
- DCGO 2015
- Country
- CELC United States
- DCGO United States
- Employees
- CELC N/A
- DCGO N/A
- Industry
- CELC Medical Specialities
- DCGO Managed Health Care
- Sector
- CELC Health Care
- DCGO Health Care
- Exchange
- CELC Nasdaq
- DCGO Nasdaq
- Market Cap
- CELC 489.7M
- DCGO 415.2M
- IPO Year
- CELC 2017
- DCGO N/A
- Fundamental
- Price
- CELC $10.93
- DCGO $4.17
- Analyst Decision
- CELC Strong Buy
- DCGO Strong Buy
- Analyst Count
- CELC 6
- DCGO 5
- Target Price
- CELC $29.17
- DCGO $6.10
- AVG Volume (30 Days)
- CELC 356.6K
- DCGO 551.0K
- Earning Date
- CELC 11-14-2024
- DCGO 02-26-2025
- Dividend Yield
- CELC N/A
- DCGO N/A
- EPS Growth
- CELC N/A
- DCGO 300.38
- EPS
- CELC N/A
- DCGO 0.29
- Revenue
- CELC N/A
- DCGO $694,968,328.00
- Revenue This Year
- CELC N/A
- DCGO $2.14
- Revenue Next Year
- CELC N/A
- DCGO N/A
- P/E Ratio
- CELC N/A
- DCGO $14.62
- Revenue Growth
- CELC N/A
- DCGO 30.19
- 52 Week Low
- CELC $10.35
- DCGO $2.75
- 52 Week High
- CELC $22.19
- DCGO $4.86
- Technical
- Relative Strength Index (RSI)
- CELC 35.65
- DCGO 48.53
- Support Level
- CELC $10.35
- DCGO $3.95
- Resistance Level
- CELC $13.80
- DCGO $4.41
- Average True Range (ATR)
- CELC 0.83
- DCGO 0.19
- MACD
- CELC -0.19
- DCGO -0.02
- Stochastic Oscillator
- CELC 16.20
- DCGO 45.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About DCGO DocGo Inc.
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company has three reportable segments: Mobile Health Services, Transportation Services, and Corporate. Mobile Health Services is the key revenue-generating segment for the company.